UNSPSC 51172137: Metaxalone

This classification denotes a muscle relaxant with the molecular formula C12H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1NMA9J598Y, chemically known as 5-((3,5-xylyloxy)methyl)-2-oxazolidinone but generally known as metaxalone, which bears US NIH Compound Identifier 15459. European Medicines Agency schedules Metaxalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08817MIG. The term METAXALONE is an International Non-Proprietary Name.

UNSPSC 51172137 Metaxalone, a Commodity code, covers muscle relaxant pharmaceutical products that state and local governments procure primarily through two channels: direct specimen collection and drug testing programs operated by corrections departments, and multi-state cooperative purchasing agreements for generic pharmaceuticals distributed to state agencies and local government facilities. Recent solicitations show corrections agencies sourcing metaxalone-containing products as part of broader drug screening panels, while state health agencies and cooperative purchasing alliances are establishing standing contracts with pharmaceutical manufacturers and wholesalers to supply generic multi-source medications including muscle relaxants to participating jurisdictions. The work encompasses both transaction-level purchasing (individual test kits and screening supplies where metaxalone detection is embedded in five- or six-panel immunoassay protocols) and supply-chain contracting (establishing vendor relationships for ongoing pharmaceutical distribution with pricing, compliance, and logistics terms negotiated upfront).

Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term with optional renewals; the scope includes approximately 25,031 annual tests across five-panel and six-panel screening configurations with LC/MS/MS or GC/MS confirmation, requiring SAMHSA, Texas DPS, or CAP lab certification. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple standing contracts for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with products effective July 1, 2026; the procurement requires cGMP and DSCSA compliance, maintains a 3 percent administrative fee structure, and applies 75 percent weight to price competitiveness in evaluation. Texas Health and Human Services Commission posted RFI HHS0017013 in late March 2026 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling potential future demand for direct contracting relationships with pharmaceutical manufacturers outside traditional PBM and wholesaler channels. Geographic activity concentrates in Texas (corrections and state health agencies) and Minnesota (cooperative purchasing), with broader multi-state participation through MMCAP's network.